{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:19:58Z","timestamp":1787959198801,"version":"build-2784847793"},"reference-count":51,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mature T-cell leukemias and lymphomas (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies. Taking advantage of recent progress deciphering the genetic basis of mTCL, we generated a comprehensive database of genetic alterations from 1825 patients with mTCL and utilized bioinformatic methodology developed to support treatment decisions in molecular tumor boards to identify novel potential therapeutics. Based on the results of this approach, we performed a systematic in vitro drug screen in molecularly characterized cell lines of mTCL to assess the activity of potential therapeutics. Of these, the cell cycle regulator WEE1 stood out as a novel therapeutic target in a genetically defined subgroup of mTCL. Indeed, WEE1 kinase inhibitors potently induced replication stress, premature mitotic entry, accumulation of DNA damage and induction of apoptosis in mTCL cell lines. Building on the single-agent activity of clinical grade WEE1 inhibitors, we next explored potential drug combination strategies through mechanistic studies. With this, we identified strong synergistic effects of combined WEE1 and JAK inhibition in genetically defined subtypes of mTCL, including primary patient samples of T-cell prolymphocytic leukemia. In summary, our study provides a comprehensive overview of the genetic landscape in mTCL and potential therapeutics in genetically defined subtypes. As such, we identified synergistic effects of dual WEE1 and JAK inhibition in cases with altered JAK\/STAT signaling as a blueprint for clinical testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015167","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:57:46Z","timestamp":1754337466000},"page":"5327-5340","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas"],"prefix":"10.1182","volume":"9","author":[{"given":"Nicole","family":"Schmidt","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3229-8592","authenticated-orcid":false,"given":"Kevin","family":"Kornrumpf","sequence":"additional","affiliation":[{"name":"2Department of Medical Bioinformatics, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Ries","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Markus","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora Anna Maria","family":"Ksionsko","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6317-0216","authenticated-orcid":false,"given":"Paolo","family":"Mazzeo","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-3292","authenticated-orcid":false,"given":"Melanie","family":"Lohrberg","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-2604","authenticated-orcid":false,"given":"Maren","family":"Sitte","sequence":"additional","affiliation":[{"name":"3NGS Integrative Genomics Core Unit, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Salinas","sequence":"additional","affiliation":[{"name":"3NGS Integrative Genomics Core Unit, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Braun","sequence":"additional","affiliation":[{"name":"4Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"5Cologne Excellence Cluster on Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany"},{"name":"6Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Dechow","sequence":"additional","affiliation":[{"name":"4Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"5Cologne Excellence Cluster on Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany"},{"name":"6Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[{"name":"4Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"5Cologne Excellence Cluster on Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany"},{"name":"6Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany"},{"name":"7Department of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Ianevski","sequence":"additional","affiliation":[{"name":"8Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[{"name":"8Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"},{"name":"9Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6485-8773","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Chapuy","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"},{"name":"10Department of Hematology, Oncology and Tumor Immunology, Charit\u00e9, University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bastians","sequence":"additional","affiliation":[{"name":"11Department of Molecular Oncology, Section for Cellular Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-2143","authenticated-orcid":false,"given":"Tim","family":"Bei\u00dfbarth","sequence":"additional","affiliation":[{"name":"2Department of Medical Bioinformatics, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"},{"name":"12Campus Institute Data Science, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-8851","authenticated-orcid":false,"given":"J\u00fcrgen","family":"D\u00f6nitz","sequence":"additional","affiliation":[{"name":"2Department of Medical Bioinformatics, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"},{"name":"12Campus Institute Data Science, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-5685","authenticated-orcid":false,"given":"Raphael","family":"Koch","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"7","key":"2025102809065189700_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"14","key":"2025102809065189700_bib2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.2019000402","article-title":"Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia","volume":"134","author":"Staber","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2025102809065189700_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"JCO"},{"issue":"12","key":"2025102809065189700_bib4","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci"},{"issue":"18","key":"2025102809065189700_bib5","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"10168","key":"2025102809065189700_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"The Lancet"},{"issue":"6","key":"2025102809065189700_bib7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"16","key":"2025102809065189700_bib8","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"JCO"},{"issue":"1","key":"2025102809065189700_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-pathol-020117-043821","article-title":"Pathogenesis of peripheral T cell lymphoma","volume":"13","author":"Pizzi","year":"2018","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"2025102809065189700_bib10","doi-asserted-by":"crossref","first-page":"a035402","DOI":"10.1101\/cshperspect.a035402","article-title":"Biology and molecular pathogenesis of mature T-cell lymphomas","volume":"11","author":"Cort\u00e9s","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"21","key":"2025102809065189700_bib11","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"De Leval","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025102809065189700_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00428-022-03412-6","article-title":"Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas","volume":"482","author":"Feldman","year":"2023","journal-title":"Virchows Arch"},{"issue":"9","key":"2025102809065189700_bib13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2025102809065189700_bib14","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","article-title":"Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers","volume":"5","author":"Rodr\u00edguez","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"2025102809065189700_bib15","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"2025102809065189700_bib16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/01.HS9.0000847552.42271.7c","article-title":"Duvelisib in patients with relapsed\/refractory peripheral t-cell lymphoma from the phase 2 primo trial: updated expansion phase analysis [abstract]","volume":"6","author":"Zinzani","year":"2022","journal-title":"HemaSphere"},{"issue":"26","key":"2025102809065189700_bib17","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025102809065189700_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards \u2014 current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2025102809065189700_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13073-018-0529-2","article-title":"From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards","volume":"10","author":"Perera-Bel","year":"2018","journal-title":"Genome Med"},{"key":"2025102809065189700_bib20","first-page":"73","article-title":"Identifying actionable variants in cancer \u2013 the dual web and batch processing tool MTB-report","volume":"296","author":"Kurz","year":"2022","journal-title":"Stud Health Technol Inform"},{"issue":"1","key":"2025102809065189700_bib21","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"2025102809065189700_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"issue":"1","key":"2025102809065189700_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"2025102809065189700_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2159-8290.CD-14-1118","article-title":"Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors","volume":"5","author":"Dienstmann","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"2025102809065189700_bib25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2025102809065189700_bib26","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2025102809065189700_bib27","first-page":"209","article-title":"Predicting the effect of variants of unknown significance in molecular tumor boards with the VUS-predict pipeline","volume":"283","author":"Schlotzig","year":"2021","journal-title":"Stud Health Technol Inform"},{"issue":"21","key":"2025102809065189700_bib28","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2025102809065189700_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"issue":"10","key":"2025102809065189700_bib30","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.celrep.2017.05.031","article-title":"PLK1 activation in late G2 sets up commitment to mitosis","volume":"19","author":"Gheghiani","year":"2017","journal-title":"Cell Rep"},{"issue":"51","key":"2025102809065189700_bib31","doi-asserted-by":"crossref","first-page":"47759","DOI":"10.1074\/jbc.C100569200","article-title":"Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress","volume":"276","author":"Ward","year":"2001","journal-title":"J Biol Chem"},{"key":"2025102809065189700_bib32","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.25.397323","article-title":"RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma","author":"Nunes","year":"26  2020","journal-title":"bioRxiv"},{"issue":"17","key":"2025102809065189700_bib33","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1182\/bloodadvances.2023009953","article-title":"TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2025102809065189700_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/2767-9764.CRC-22-0168","article-title":"Replication stress defines distinct molecular subtypes across cancers","volume":"2","author":"Takahashi","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"1","key":"2025102809065189700_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025102809065189700_bib36","doi-asserted-by":"crossref","first-page":"e2024004","DOI":"10.4084\/MJHID.2024.004","article-title":"Successful bridging to allogeneic transplantation with valemetostat in two refractory\/relapsed peripheral T-cell lymphoma patients","volume":"16","author":"Bagnato","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"7","key":"2025102809065189700_bib37","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.3390\/ijms23073834","article-title":"Targeting the DNA damage response to increase anthracycline-based chemotherapy cytotoxicity in T-cell lymphoma","volume":"23","author":"Magni","year":"2022","journal-title":"IJMS"},{"issue":"6","key":"2025102809065189700_bib38","doi-asserted-by":"crossref","first-page":"e15816","DOI":"10.15252\/emmm.202215816","article-title":"A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability","volume":"14","author":"Kuczynski","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2025102809065189700_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-018-0641-1","article-title":"Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia","volume":"11","author":"Ghelli Luserna Di Ror\u00e0","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025102809065189700_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna Di Ror\u00e0","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2025102809065189700_bib41","doi-asserted-by":"crossref","first-page":"110261","DOI":"10.1016\/j.celrep.2021.110261","article-title":"WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity","volume":"38","author":"Elb\u00e6k","year":"2022","journal-title":"Cell Rep"},{"issue":"5","key":"2025102809065189700_bib42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","article-title":"Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation","volume":"28","author":"Pfister","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"2025102809065189700_bib43","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"2025102809065189700_bib44","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1535-7163.MCT-14-0735-T","article-title":"Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence","volume":"14","author":"Osman","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2025102809065189700_bib45","first-page":"908","article-title":"mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers","volume":"10","author":"Li","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2025102809065189700_bib46","doi-asserted-by":"crossref","first-page":"2237342","DOI":"10.1080\/16078454.2023.2237342","article-title":"Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia","volume":"28","author":"Brothers","year":"2023","journal-title":"Hematology"},{"issue":"suppl 1","key":"2025102809065189700_bib47","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2021-149228","article-title":"Preliminary study of ruxolitinib and venetoclax for treatment of patients with T-cell prolymphocytic leukemia refractory to, or ineligible for alemtuzumab","volume":"138","author":"Herbaux","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025102809065189700_bib48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41467-017-02688-6","article-title":"Actionable perturbations of damage responses by TCL1\/ATM and epigenetic lesions form the basis of T-PLL","volume":"9","author":"Schrader","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2025102809065189700_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000506302","article-title":"Patterns of late relapse after allogeneic hematopoietic stem cell transplantation in patients with T-cell prolymphocytic leukemia","volume":"144","author":"Shumilov","year":"2021","journal-title":"Acta Haematol"},{"issue":"10","key":"2025102809065189700_bib50","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1182\/blood.V91.10.3920.3920_3920_3926","article-title":"Inactivation of the ATM gene in T-cell prolymphocytic leukemias","volume":"91","author":"Stoppa-Lyonnet","year":"1998","journal-title":"Blood"},{"issue":"17","key":"2025102809065189700_bib51","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.1021\/acs.jmedchem.1c01121","article-title":"Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer","volume":"64","author":"Huang","year":"2021","journal-title":"J Med Chem"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5327\/2417351\/blooda_adv-2024-015167-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5327\/2417351\/blooda_adv-2024-015167-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:07:07Z","timestamp":1761656827000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5327\/546473\/Discovery-of-molecularly-informed-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":51,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015167","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,17]]}}}